share_log

Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $9

Benzinga ·  Oct 16, 2023 13:34

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $13 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment